Hormonal evaluation in relation to phenotype and genotype in 286 patients with a disorder of sex development from Indonesia.

ObjectiveThe objective of this study was to determine the aetiological spectrum of disorders of sex development (DSD) in a large cohort of underprivileged and undiagnosed patients from Indonesia. MethodsA total of 286 patients with atypical external and/or internal genitalia were evaluated using clinical, hormonal, molecular genetic and histological parameters. ResultsThe age (years) at presentation was 0-05 in 41 (143%), >05-12 in 181 (633%) and >12 in 64 cases (224%). 46,XY DSD was most common (682%, n = 195), 46,XX DSD was found in 234% (n = 67) and sex chromosomal DSD in 84% (n = 24). In 612% of 46,XX DSD patients, 179% of 46,XY DSD patients and all sex chromosome DSD patients (294% in total), a final diagnosis was reached based on genetic or histological gonadal tissue evaluation. 17-hydroxyprogesterone and androstenedione levels were the most distinctive parameters in 46,XX DSD patients. In 46,XY DSD, diagnostic groups were identified based on the external masculinization score: androgen action disorder (AAD), unknown male undermasculinization (UMU), and gonadal dysgenesis (GD). LH, FSH and testosterone levels were most informative especially in the older age group. HCG tests were of no additional value as no patients with androgen synthesis disorders were found. Hormonal profiles of patients with sex chromosome DSD and a Y-chromosome sequence containing karyotype showed high levels of LH and FSH, and low levels of AMH, inhibin B and testosterone compared with the normal male range. Gene mutations were found in all patients with CAH, but in only 245% and 18% of patients with AAD and UMU. In 32% of 46,XY GD patients, copy number variants of different genes were found. ConclusionA stepwise diagnostic approach led to a molecularly or histologically proven final diagnosis in 294% of the patients. The most informative parameters were serum levels of 17-hydroxyprogesterone and androstenedione in 46,XX DSD patients, and serum LH, FSH and testosterone levels in 46,XY DSD patients.